Overview

Polycystic Liver Disease in Kidney Transplant

Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if one kind of immunosuppressive drug has better effects for the patient's polycystic liver disease than another type. Tacrolimus and Sirolimus are the two immunosuppressive drugs that will be compared for this study. Both drugs have been commonly prescribed to prevent rejection.
Phase:
N/A
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Everolimus
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Sirolimus
Tacrolimus